Why choose QIAseq Multimodal technology?
Recent advances in NGS and bioinformatics have empowered researchers to efficiently interrogate DNA and RNA modifications in biological samples. However, current approaches require two separate workflows for DNA and RNA library preparation, each with inherent bias. Having different workflows increases costs and turnaround times, ultimately delaying the acquisition of actionable data. Limited sample availability can also impact your ability to achieve comprehensive genomic and transcriptomic insights.
One sample, one workflow and one day is all you need
Maximize the information you derive from a single total nucleic acid sample by simultaneously profiling DNA and RNA biomarkers in one consolidated workflow and just one day. With QIAseq Multimodal technology, you can interrogate various biomarkers in the same, single-day workflow from as little as 10 ng of sample.
Dr. Vincent Funari, Vice President of Research and Development at NeoGenomics Laboratories
Multimodal sequencing
Go from sample to sequencing in a day
-
Achieve high-confidence data
- Detect rare variants
- Reduce index hopping and read mis-assignment
-
Get complete coverage
- Find known and novel fusions
- Cover GC-rich regions
- Superior customization
-
Save sample, time and costs
- Multiple insights from a single extraction and workflow
- Reduce turnaround time and costs by 50%
Custom design
Comprehensive genomic profiling
Comprehensive genomic profiling (CGP) is dramatically changing our understanding of various cancers, revealing an unprecedented level of detail. Multimodal sequencing can accelerate this rapidly evolving field of research.
Top 3 reasons to adopt a multimodal approach for CGP:
- Save time and resources: Consolidate separate workflows into a single-day, sample to sequencing workflow.
- Conserve precious samples: Simultaneously profile multiple DNA and RNA biomarkers, TMB and MSI from a single, low-input sample.
- Get deeper insights: Achieve a holistic view of various cancer biomarkers efficiently.
What can you profile with the QIAseq Pan-cancer Multimodal Panel?
-
Gene targetsProfiling of DNA variants in solid and hematologic malignancies
QIAseq: Covers exonic regions +5–10 bases of exon/intron junctions
-
RNA fusionsA hybrid gene formed from two previously discrete genes, implicated in tumorigenesis
QIAseq: Targets transcripts in COSMIC, covers exons in both 3’ and 5’ directions
-
Tumor mutational burdenThe measure of the number of mutations found within a tumor, which can indicate treatment response
QIAseq: Coverage of >1 Mb enables statistically significant assessment of TMB
-
Microsatellite instability statusChanges in microsatellites, or repeat regions, associated with various cancers
QIAseq: 26 loci with well-established utility for correlation to treatment response
Explore the QIAseq Pan-cancer Multimodal Panel
Watch the webinars
-
Evolution of tumor profiling in a clinical lab: Moving toward comprehensive genomic profiling
In this webinar, Vincent Funari of NeoGenomics will discuss how his team has evolved its profiling approaches for both heme and solid tumors from targeted panels to more comprehensive genomic profiling.
-
Comprehensive genomic profiling of solid tumors and heme malignancies
In this webinar, we discuss how you can uncover insights into multiple cancers from just 1 ng total nucleic acid using the QIAseq Pan-cancer Multimodal Panel. Learn about the technology and how it can ensure superior coverage while saving time and costs.
-
One-day workflow for simultaneous profiling of DNA variants and RNA fusions
In this webinar, we explore a new workflow for simultaneous NGS profiling of both DNA variants and RNA fusions, as well as gene expression in just one day, using as little as 10 ng sample.
-
Analyzing multimodal data with QIAGEN CLC Genomics Workbench
In this webinar, we will take you through an introduction and live demo of the QIAGEN CLC Genomics Workbench workflow for multimodal analysis. Discover this intuitive yet powerful solution tailored for analysis of NGS data generated with QIAseq Multimodal Panels.
-
Evolution of tumor profiling in a clinical lab: Moving toward comprehensive genomic profiling
-
Comprehensive genomic profiling of solid tumors and heme malignancies
-
One-day workflow for simultaneous profiling of DNA variants and RNA fusions
-
Analyzing multimodal data with QIAGEN CLC Genomics Workbench